Starting co-promotion of the anti-cancer agent “SPRYCEL® Tablet 20mg and SPRYCEL® Tablet 50mg” (dasatinib) in Japan

The results of a subset analysis of Japanese patients from the DASISION trial comparing SPRYCEL®(dasatinib) with imatinib in the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.

World's First Aquaretic Agent for the Treatment of Volume Overload in Patients with Heart Failure
Samsca® Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, to be Launched in Japan on December 14

Tokushima Itano Factory
Recognized Among "Corporate Greening Linked to Conservation of Biodiversity: Best 100"
Sole factory manufacturing medical-use pharmaceuticals to receive recognition

Follow-Up Results from Study Comparing SPRYCEL® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data

Toward a Factory that is Friendly to Both the Environment and People the Tokushima Itano Factory Helps to Support the Asan Earth Festival in Itano to be Held on November 23, 2010

Otsuka Pharmaceutical Files Application in Japan for Additional Indication of L-Cartin® Tablets for Carnitine Deficiency, Based on Evidences in Public Domain

Otsuka Prevails in U.S. Abilify® Patent Litigation

Clinical tests in Japan demonstrate research results relating to the efficacy of "Ion supply drink" for dehydration after bathing

Otsuka Pharmaceutical Files for Regulatory Approval in Japan for Mucosta® Ophthalmic Suspension for Dry Eye

FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase

SAMSCA™ Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, Receive Regulatory Approval in Japan

New Release of Medicated Skin Wash in 500mL Pump-style Economy Size and Refill Pouch Available from November 12, 2010

OTSUKA ANNOUNCES PHASE 3 ARIPIPRAZOLE INTRAMUSCULAR (IM) DEPOT TRIAL INTERIM ANALYSIS REVEALS EFFICACY CRITERIA MET

OTSUKA OPENS FIRST OFFICE IN CANADA
Important Milestone for Growing North American Pharmaceutical Operations

Tweet Runners app for iPhone released on September 29th
Tweet Runners and Amino-Value keep runners going

Otsuka Pharmaceutical and Acucela Enter New Co-Development and
Co-Promotion Agreement for OPA-6566 for Glaucoma

Antiepileptic Drug 'E Keppra® Tablet' with New Mechanism of Action
Released on September 17

The Results of CSPS 2, a Large-scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Published in The Lancet Neurology Online

Renewed Package Design for Nature Made
America's number one-selling vitamin, mineral and supplement brand

Construction of 'OPS-5', New Plant to Manufacture Active Pharmaceutical Ingredients in Saga Factory Completed on September 1

Publication of Environmental and Social Report 2010
- Featuring approaches to help build a low-carbon, recycling-oriented society, development of environment-conscious products and social action programs -

21st Annual Outdoor Concert Held at Otsuka Pharmaceutical Tokushima Wajiki Factory Exciting Summer in Wajiki '10 on August 13, 2010

E Keppra® (levetiracetam) receives regulatory approval in Japan

SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase

GW and Otsuka Agree Three Year Extension
to Global Cannabinoid Research Collaboration

Otsuka receives approval for Rapirun® H. Pylori Antibody Stick as in vitro diagnostic device on June 8, 2010

Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors (PDF:39KB)

Four-Year Follow-Up Data for SPRYCEL® (dasatinib)Demonstrate 82 Percent Overall Survival
in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®

SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic
Response Rates Compared to Gleevec® in Study of Adult Patients with Newly Diagnosed
Chronic Myeloid Leukemia in Chronic Phase

Streptococcus pneumoniae Kit "RAPIRUN Pneumococcus" Approval obtained as in vitro diagnostic on May 26

First reader-participation collaboration
OTSUKA Health Comic Library Sequel Vol. 3
“We Are Children of the Earth: The Environment & Our Health”
March 31 publication for donation to elementary schools nationwide

Otsuka Pharmaceutical and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD

FerriSeltz® powder 20%, MRI Oral GI Contrast Agent, Receives Additional Approval for GI Negative Imaging in Cholangiopancreatography

Rapid Assay Kit for RS virus, QUICKNAVI™-RSV, Launch on April 6

In-vitro Diagnostic Kit, WT1 mRNA Assay Kit "Otsuka" Application Filed for Additional Purpose of Use with Myelodysplastic Syndromes

New Medicated Skin Wash from UL･OS Line of Men's Face & Body Care Available from April 22, 2010

The Results of CSPS II, a Large-scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Presented at American Stroke Association's International Stroke Conference on February 26

French Health Food Brand Gerblé to Debut in Japan Made from rigorously selected natural ingredients in southern France Test Marketing Begins April 6, 2010

InnerSignal UV Protect Make-up Base b Will Be Launched on March 1, 2010

Otsuka Pharmaceutical Co., Ltd. and Fuso Pharmaceutical Industries, Ltd. Conclude Agreement for the Manufacturing and Commercialization of Therapeutic Cancer Vaccine, OTS102